The announcement of a 1-for-20 reverse stock split by NeuBase Therapeutics has led to a decrease in its share price. Reverse stock splits often lead to a decline in share price as they are perceived negatively by investors, who may see it as a sign of financial distress or an attempt to meet listing requirements.